Friedl Yvonne, Schulz Bianka, Knebl Anne, Helps Chris, Truyen Uwe, Hartmann Katrin
Clinic of Small Animal Medicine, Ludwig-Maximilians-Universitaet Munich, Veterinaerstrasse 13, 80539 Munich, Germany.
Clinic of Small Animal Medicine, Ludwig-Maximilians-Universitaet Munich, Veterinaerstrasse 13, 80539 Munich, Germany.
Vet J. 2014 Sep;201(3):316-21. doi: 10.1016/j.tvjl.2014.05.002. Epub 2014 May 6.
A commercial hyperimmune serum, containing antibodies against feline calicivirus (FCV), feline herpesvirus 1 (FHV-1), and feline panleukopenia virus, is available for treatment of cats with feline upper respiratory tract disease (FURTD), but its efficacy has not been rigorously evaluated in scientific studies. The aim of this randomised, placebo-controlled, double-blind clinical trial was to evaluate the efficacy of passive immunisation in cats with acute viral FURTD caused by FCV and/or FHV-1 infection. All cats received symptomatic treatment during the study period. Hyperimmune serum was administered to one group (n = 22) and an equivalent amount of saline was administered to the control group (n = 20) as placebo, for 3 consecutive days. In the treatment group, cats ≤12 weeks old received 2 mL, cats >12 weeks old received 4 mL, subcutaneously once daily and topically into eyes, nostrils, and mouth every 8 h. Clinical signs, including a 'FURTD score' and general health status, were recorded daily for 8 days and again on day 21. FCV shedding was determined by quantitative PCR on days 0 and 21. Clinical signs and health status in both groups improved significantly over time (P < 0.001). Cats receiving hyperimmune serum significantly improved in terms of 'FURTD score' (P = 0.046) and general health status (P = 0.032) by day 3, while cats in the placebo group only improved significantly by day 7. There was no significant difference in the number of cats shedding FCV between the two groups. Thus, administration of hyperimmune serum led to a more rapid improvement of clinical signs in cats with acute viral FURTD, but by day 7, clinical signs had improved equally in both groups.
一种含有抗猫杯状病毒（FCV）、猫疱疹病毒1型（FHV-1）和猫泛白细胞减少症病毒抗体的商业超免疫血清可用于治疗患有猫上呼吸道疾病（FURTD）的猫，但尚未在科学研究中对其疗效进行严格评估。这项随机、安慰剂对照、双盲临床试验的目的是评估被动免疫对由FCV和/或FHV-1感染引起的急性病毒性FURTD猫的疗效。在研究期间，所有猫都接受了对症治疗。一组（n = 22）给予超免疫血清，对照组（n = 20）给予等量生理盐水作为安慰剂，连续3天。在治疗组中，≤12周龄的猫皮下注射2 mL，>12周龄的猫皮下注射4 mL，每天1次，每8小时眼部、鼻孔和口腔局部给药一次。每天记录临床症状，包括“FURTD评分”和总体健康状况，持续8天，并在第21天再次记录。在第0天和第21天通过定量PCR测定FCV排毒情况。两组的临床症状和健康状况均随时间显著改善（P < 0.001）。到第3天，接受超免疫血清的猫在“FURTD评分”（P = 0.046）和总体健康状况（P = 0.032）方面有显著改善，而安慰剂组的猫直到第7天才有显著改善。两组之间FCV排毒猫的数量没有显著差异。因此，给予超免疫血清可使急性病毒性FURTD猫的临床症状更快改善，但到第7天，两组的临床症状改善程度相同。
